Ranibizumab biosimilar (CJSC Generium)

雷珠单抗生物类似药（CJSC Generium）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRanibizumab biosimilar (CJSC Generium)

Drug Alias NameAnti-VEGF fragment (CJSC Generium)雷珠单抗生物仿制药（CJSC Generium）rhuFab V2 AMD (CJSC Generium)Ranibizumab (CJSC Generium)Rabinismab (CJSC Generium) +[8]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCjsc Generium

China Registration ClassN/A

Develop Information

Active CompaniesCjsc Generium

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeS01LA04